Piper Sandler Reiterates Jazz Pharmaceuticals Buy Rating

Summary

Piper Sandler reiterated a Buy rating on Jazz Pharmaceuticals with a $147.00 price target, suggesting a 42.73% upside. The consensus among analysts is a Strong Buy with an average price target of $184.69.Tip Ranks

Impact Analysis

So basically, Piper Sandler’s reiteration of a Buy rating for Jazz Pharmaceuticals at $147.00 is a strong signal, especially when the consensus price target is $184.69, indicating a 42.73% upside.Tip Ranks The interesting part isn’t just the Buy rating but the timing and the context. Jazz Pharmaceuticals recently missed its quarterly EPS estimates and has set a conservative FY 2025 guidance.Market Beat Despite this, the stock has strong technical indicators, including a long-term uptrend and a MACD golden cross, suggesting bullish momentum. However, the short-term technicals are less favorable, indicating potential volatility. The market seems to be underestimating the stock’s potential, given the mixed financials and recent insider selling.TradingView This could be an opportunity to buy on dips, especially if the stock approaches its support levels around $123.88. Keep an eye on volume trends and any updates on their marketing strategy for Modeyso, which could be a catalyst for upward movement.MSN